TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Operations
(in thousands, except share and per share data)
| 2024 | 2023 | |
|---|---|---|
| Revenue | $29,431 | 18,511 |
| Cost of goods sold | 4,103 | 2,605 |
| Gross profit | 25,328 | 15,906 |
| Operating expenses: | ||
| Research and development | 17,688 | 29,835 |
| Sales and marketing | 25,839 | 17,034 |
| General and administrative | 17,966 | 23,512 |
| Loss from operations | (36,165) | (54,475) |
| Other income (expense) | ||
| Interest income | 404 | 431 |
| Interest expense | (3,090) | (16) |
| Loss on equity issuance | — | (5,874) |
| Extinguishment of tranche liability | — | 1,520 |
| Change in fair value of warrant, SEPA, and revenue base redemption liabilities | (2,107) | (10,855) |
| Change in fair value of contingent earnout liability | 11,231 | 10,293 |
| Other expenses, net | (312) | (378) |
| Loss before income taxes | (30,039) | (59,354) |
| Income tax expense | (6) | (9) |
| Net loss available to common stockholders | $(30,045) | $(59,363) |
| Deemed dividend related to Series B-2 preferred stock down round provision | $— | $(2,981) |
| Undeclared dividends on Series A preferred stock | $(3,188) | $(1,258) |
| Net loss attributable to common stockholders | $(33,233) | $(63,602) |
| Net loss per share, basic and diluted | $(1.31) | $(6.77) |
| Weighted average common shares outstanding, basic and diluted | 25,331,753 | 9,395,748 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.